Key Moments
402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
Peter Attia MDWant to know something specific about what's covered?
We've already dissected every moment. Ask and we will deliver (with timestamps).
Key Moments
A single blood test using NMR can predict mortality risk years in advance, but healthcare systems are slow to adopt these advanced diagnostics.
Key Insights
NMR spectroscopy, initially flawed for cancer detection, evolved to measure lipoprotein particle concentrations (LDL-P) and sizes, which are better predictors of cardiovascular risk than traditional LDL cholesterol.
The MVX score, a composite marker derived from NMR analysis of plasma, demonstrates remarkable predictive power for all-cause mortality, even in young and healthy individuals, and is largely independent of age.
Traditional lipid panels, which often rely on estimations and lack precision (e.g., calculating LDL-C from triglycerides), miss crucial information about lipoprotein particle number and size that contribute significantly to cardiovascular disease risk.
The LPIR score, derived from NMR data, shows promise in assessing insulin resistance and predicting diabetes risk, acting as an early warning system before glucose levels become elevated.
Despite strong scientific evidence for advanced NMR-based biomarkers like LDL-P and MVX, clinical translation and widespread adoption are hindered by resistance from the medical establishment and reimbursement challenges.
The MVX score's components (small HDL particles, glycan inflammation markers, citrate, and branched-chain amino acids) offer a comprehensive view of metabolic health and mortality risk, with its predictive power observed across diverse populations, including those with and without chronic diseases.
From flawed cancer test to lipid insights: The origin of NMR blood analysis
The journey of using Nuclear Magnetic Resonance (NMR) spectroscopy for clinical diagnostics began with a mistaken premise. In the 1980s, a widely publicized study in the New England Journal of Medicine claimed a simple NMR test on blood plasma could detect cancer. Dr. Jim Otvos, using his expertise in NMR spectroscopy, investigated this claim. He discovered that the 'cancer signal' was not related to cancer itself but to variations in lipid and lipoprotein levels, specifically higher triglycerides and lower HDL cholesterol, which are common in cancer patients. This realization pivoted the research focus from cancer to understanding lipoproteins. By analyzing the NMR signals, Otvos and his team found they could differentiate and quantify different types of lipoproteins like VLDL, LDL, and HDL, and even their subspecies based on size. This opened the door to measuring lipoprotein particle concentrations (like LDL-P) and sizes, which, as research later showed, are more potent indicators of cardiovascular risk than traditional cholesterol measurements.
Limitations of standard lipid panels
Traditional lipid panels, which have been the cornerstone of cardiovascular risk assessment for decades, often rely on indirect measurements and chemical assays. For example, LDL cholesterol (LDL-C) is frequently calculated using the Friedewald equation, which estimates VLDL cholesterol by dividing triglyceride levels by five. This method is prone to inaccuracies, especially when triglyceride levels are high or low. Furthermore, standard assays measure the cholesterol *within* lipoprotein particles, not the number or size of the particles themselves. This overlooks critical information; for instance, individuals with a predominance of small, dense LDL particles can have high cardiovascular risk even with seemingly normal LDL-C levels, a nuance traditional tests miss entirely. The development of NMR-based assays allows for the direct measurement of lipoprotein particle number (LDL-P) and size, providing a more granular and accurate picture of cardiovascular risk.
The power of particle number: LDL-P and cardiovascular risk
A key revelation from NMR lipid analysis is the importance of lipoprotein particle number, particularly LDL-P. Research, including studies from the Framingham and MESA populations, has shown that when LDL particle number (LDL-P) and LDL cholesterol (LDL-C) are discordant (i.e., they don't align), the LDL-P is a more reliable predictor of cardiovascular events. This discordance often occurs when LDL particles are smaller. While larger, 'fluffy' LDL particles carry more cholesterol, smaller particles are thought to penetrate the arterial wall more easily and contribute more to atherosclerosis. The finding that cardiovascular risk tracks with particle number, rather than just cholesterol content, suggests that simply lowering LDL-C might not be sufficient if the particle number remains high. This highlights the clinical utility of LDL-P as a biomarker for guiding more aggressive lipid-lowering therapy when necessary.
Beyond lipids: NMR's role in metabolic health and diabetes risk
The utility of NMR extends beyond cardiovascular risk assessment. Dr. Otvos's company, Liposcience, developed the LPIR score, which utilizes NMR data to assess insulin resistance and predict the likelihood of developing type 2 diabetes. This score integrates information about the size and subclass concentrations of VLDL, LDL, and HDL particles. The rationale is that insulin resistance has a distinct lipid signature. By measuring this signature, the LPIR score can identify individuals at risk for diabetes years before their glucose levels become significantly elevated, offering a window for early intervention. This approach is particularly valuable because, unlike easily measured glucose, insulin resistance itself is harder to assess directly in routine clinical practice, and by the time glucose levels rise, significant beta-cell dysfunction may have already occurred.
The MVX score: A novel predictor of mortality
The most profound development discussed is the MVX score, a composite biomarker derived from a single NMR spectrum. This score, which includes components like small HDL particles, glycan inflammatory markers, citrate, and branched-chain amino acids, has demonstrated remarkable predictive power for all-cause mortality across various populations. Astonishingly, the MVX score shows significant predictive value even in young, healthy individuals (aged 25-30) and is largely unassociated with age. This suggests MVX may reflect a fundamental metabolic vulnerability or susceptibility to dying, rather than simply predicting the diseases that cause death. The components of MVX are measured with remarkable analytical efficiency and low cost using NMR, offering a comprehensive snapshot of an individual's health status.
Challenges in clinical translation and future directions
Despite the compelling scientific evidence and the potential of NMR-based diagnostics like LDL-P and MVX, their widespread clinical adoption faces significant hurdles. Dr. Otvos highlights resistance from the medical establishment, a lack of familiarity with NMR technology in clinical labs, and complex reimbursement landscapes as major barriers. The commercialization of Liposcience, initially aimed at making NMR analyzers accessible to laboratories worldwide, ultimately transitioned to LabCorp, shifting the focus from broad accessibility to proprietary testing. This has slowed the dissemination of these advanced diagnostic tools. The future success of these technologies may depend on demonstrating their value in ways that align with healthcare economics, potentially by integrating multiple markers into cost-effective panels or by showing clear benefits in therapeutic selection and intervention, particularly for complex conditions like metabolic syndrome and diabetes.
Mentioned in This Episode
●Products
●Software & Apps
●Companies
●Organizations
●Books
●Drugs & Medications
●Studies Cited
●Concepts
●People Referenced
Common Questions
NMR spectroscopy is a structural tool in chemistry that helps determine molecular structure. It was serendipitously applied to blood analysis after a 1986 New England Journal of Medicine paper claimed a simple NMR test could detect cancer. The guest's research debunked this by showing the signal was related to lipoproteins, not cancer, but this led to the development of lipoprotein quantification by NMR.
Topics
Mentioned in this video
Host of The Drive Podcast.
Introduced Peter Attia to the guest's work in 2011.
Researcher at UC Berkeley's Donner Laboratory who showed that small dense LDL conferred greater cardiovascular risk, which motivated the guest to apply NMR to differentiate lipoprotein sizes.
A prominent proponent of APOB, with whom the guest has collaborated rather than competed, in advocating for its importance in risk assessment.
A structural tool used in chemistry and biochemistry, enabling the determination of molecular structure and later adapted for quantitative analysis of lipoproteins.
A laborious separation method used by Ron Krauss to differentiate LDL based on size, which NMR later proved capable of doing more efficiently.
A prestigious medical journal that published a paper in 1986 claiming a simple NMR test could diagnose cancer, which spurred the guest's initial research into NMR of blood plasma.
A journal where the guest published a paper in 1990 or 1991, showing that NMR signals from isolated lipoproteins of cancer patients did not differ from healthy individuals.
The institution where the guest had an appointment in chemistry before moving to North Carolina State University.
The institution where the guest moved in 1990 after his time at the University of Wisconsin-Milwaukee.
The US Food and Drug Administration, which cleared the Vanta analyzer for LDLP in 2011, marking a significant regulatory hurdle for NMR technology in clinical use.
One of the major laboratories that received Vanta analyzers from Liposcience before its acquisition by LabCorp.
One of the major laboratories that received Vanta analyzers from Liposcience before its acquisition by LabCorp.
One of the major laboratories that received Vanta analyzers from Liposcience before its acquisition by LabCorp.
Provided initial funding for the guest's research into NMR of plasma after a one-hour presentation, which was crucial for developing the lipoprotein analysis.
A company founded by the guest to commercialize NMR testing, initially focusing on LDLP and later acquired by LabCorp.
Acquired Liposcience and its NMR testing technology, but did not pursue the IVD (in vitro diagnostics) vision for broad distribution.
A large NIH-funded study that provided baseline samples for NMR analysis, yielding significant data for MVX and other biomarker discoveries.
A long-running observational study that provided data for early research on LDL particle size and cardiovascular risk, and later for LPIR and MVX validation.
A large study with 26,000 women at baseline, providing samples for NMR analysis and long-term follow-up for biomarker development.
Mentioned as one of the intervention trials that provided samples for NMR analysis to assess biomarker efficacy.
A study that placed lifestyle intervention and Metformin on the map for preventing diabetes, also used for LPIR score validation and showing its reduction with interventions.
A medication used for diabetes prevention and treatment, shown to reduce LPIR scores, though less significantly than lifestyle changes.
A checkpoint inhibitor and bestselling drug in oncology, used as an example for how MVX could predict patient response to therapeutic interventions in cancer.
A CETP inhibitor drug discussed in relation to its impact on LDL-P and LDL-C, and the complexities of NMR analysis of HDL particles in its presence.
A signal in the NMR spectrum reflecting carbohydrate decoration on acute phase proteins, serving as a stable and useful marker of systemic inflammation.
One of the three components of the MVX metabolic score, along with branched-chain amino acids, contributing to the prediction of mortality.
Three amino acids (isoleucine, leucine, valine) that are part of the MVX metabolic score. High levels relate to insulin resistance, while low levels are associated with mortality risk.
More from Peter Attia MD
View all 338 summaries
118 minBuilding strength and muscle mass: optimize training & nutrition for longevity (AMA #71 rebroadcast)
121 min397 - Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, & emerging treatments
51 min396 – Breast cancer screening: understanding risk, deciding when to start, and more
105 min395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free